Nordic Pharma has acquired ALTIM® (cortivazol) pre-filled syringe to strengthen their Rheumatology portfolio

News

Nordic Pharma has acquired ALTIM® (cortivazol) pre-filled syringe to strengthen their Rheumatology portfolio

Nordic Pharma has acquired ALTIM® (cortivazol) pre-filled syringe to strengthen their Rheumatology portfolio
febrero 7, 2022 marpalop
nordic-pharma-espana-colaboraciones-con-las-organizaciones-de-pacientes-2020
Date
Category Corporativo Nordic Phama

Paris, January 2022 – Nordic Pharma is pleased to announce that they have entered into an agreement with SANOFI to fully acquire the rights to ALTIM® (cortivazol), a legacy product in France.

ALTIM® contains a 3.75mg/1.5ml cortivazol suspension for injection, presented in a pre-filled syringe, and is approved in France in Rheumatology indications, where a local corticosteroid treatment is required.
See prescribing information: Résumé des caractéristiques du produit – ALTIM 3,75 mg/1,5 ml, suspension injectable en seringue pré-remplie – Base de données publique des médicaments (medicaments.gouv.fr)

This acquisition supports Nordic Pharma’s strategy to grow its proprietary portfolio and to become a key player in Rheumatology in France and beyond.

ALTIM® was commercialized in France since the 70’s and subsequently withdrawn from the French market by Sanofi in 2018 due to manufacturing issues. It is the intention of Nordic Pharma to re-engineer the process and the manufacturing for both the active substance and the finished product to allow the product to be re-launched onto the French market at the earliest possibility as the product is still requested by clinicians.

Jean-Michel Quinot, CEO of Nordic Pharma stated:” We are very pleased to have reached an agreement with Sanofi allowing us to re-introduce ALTIM® into the French market. Nordic Pharma is dedicated to providing Patients and Physicians with innovative medications addressing significant unmet medical needs. We are very eager to further expand our successful collaboration with Sanofi.”

Veronique Rebours-Mory, CSO of Nordic Pharma stated: “Physicians are still demanding this unique treatment option for Rheumatology patients, and despite the challenge and investment needed, we are committed to solving the manufacturing issues that led to the discontinuation of the product.”

 

About Nordic Pharma

Nordic Pharma is a privately owned, medium-size, fully integrated Pharma company with a history of internal product development and acquisitions. We have established deep roots throughout Europe, and more recently, expanded in North America and Japan, with increased partnerships worldwide.

Nordic Pharma focusses on the development and commercialization of specialty products, which include, but are not limited to, niche hospital and orphan products, to address unmet medical needs. Today, Nordic Pharma has a range of highly specialized proprietary and in-licensed products in the following therapeutic areas: Rheumatology, Women’s Health and Critical Care (Anaesthesiology, Haematology, Oncology).

https://www.nordicpharma.com/

 

About Sanofi

Sanofi is dedicated to supporting people through their health challenges. We are a global biopharmaceutical company focused on human health. Sanofi prevent illness with vaccines, provide innovative treatments to fight pain and ease suffering. Sanofi stand by the few who suffer from rare diseases and the millions with long-term chronic conditions. With more than 100,000 people in 100 countries, Sanofi is transforming scientific innovation into healthcare solutions around the globe.

https://www.sanofi.com/

0 Comentarios

Dejar una respuesta

Tu dirección de correo electrónico no será publicada.

*